Jia (Zack) Shen

biomedical researcher at NCI-designated Cancer Center of Sanford Burnham Prebys Medical Discovery Institute

Sanford | Burnham | Prebys Medical Discovery Institute, 10901 N Torrey Pines Rd, La Jolla, CA 92037

biography

I am Jia (Zack) Shen, now I am a biomedical researcher at NCI-designated Cancer Center of Sanford Burnham Prebys Medical Discovery Institute. The Institute ranks among the top independent research institutions nationally for NIH grant funding and among the top organizations worldwide for its research impact. From 1999 – 2009, Sanford-Burnham ranked #1 worldwide among all types of organizations in the fields of biology and biochemistry for the impact of its research publications, ranks #2 nationally among all organizations in capital efficiency of generating patents, defined by the number of patents issued per grant dollars awarded. I got my Ph.D. studies at the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, the premier scientific institute for biomedical research in China, my research continually focused on cancer biology and cancer nanotechnology. These studies lead to several important findings in cancer research, including identifying a novel mechanism for iron-overload in cancer development (Shen et al.,Cell Rep, 2014; Shen et al., Mol Cell Oncol, 2016; highlighted by Chemistry & Biology, 2014; Global Medical Discoveries, 2014), and developing a bio-nanotech system for for improving drug efficacy for treatment of non-small cell lung cancers (NSCLCs) (Shen et al., Biomaterials, 2014). The publication has been cited >40 times within the following 2 years. After that, I as the corresponding author further developed this research strategy and used the improved system for P53 gene mutant NSCLS therapy (Li et al., Biomaterials Science, 2016). Besides, I’m also involved in various of nano-materials projects through collaboration (see publication below). In addition, I have been a reviewer for many scientific journals (review times >30) including Biomaterials (IF 8.5), Cellular Physiology and Biochemistry (IF 4.65), Cancers (IF 4.5), Biomaterials Science (IF 3.8), Chinese Journal of Cancer Research (IF 1.94), Frontier of Medicine (IF 1.86) and other international journals. At the same time, I serve as the editor for 2 international journals.

 

Area of Interest

Biomaterials; Drug delivery; Gene delivery; Nanoparticle Targeting; Biomarker study; Cellular signal pathways; Nature product.


top publication

 Jia Shen, Guosheng Song, Man An, Xianqian Li,Ning Wu,KangchengRuan, Junqing Hu,Ronggui Hu. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy. Biomaterials 2014,1(35):316-26.

 Jia Shen, Xiangpeng Sheng, ZeNan Chang, Qian Wu, Sheng Wang, ZongliangXuan, Yalan Wu, Xiangtao Kong, Long Yu, Lin Li, KangchenRuan, Hongyu Hu, Ying Huang, Fudi Wang, Ronggui Hu. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulating localization, stability and function of p53.Cell Reports 2014,7:1-14.

 Jia Shen, Xiangpeng Sheng, ZeNan Chang, Qian Wu, Dong Xie, Fudi Wang, Ronggui Hu. The heme–p53 interaction: Linking iron metabolism to p53 signaling and tumorigenesis. Molecular & Cellular Oncology 2016, 3:1, e965642.

 Jia Shen, Fudi Wang, Ronggui Hu. Recent advance on crosstalk between iron metabolism and cellular protein ubiquitylation and degradation. Life Science 2012, 24(8): 785-793.

 Jia Shen, Charles Spruck. F-Box Proteins in Epigenetic Regulation of Cancer. Journal of Cancer Biology & Research 2016, 4(3): 1088.

 Jia Shen, Shengping Zhang, Yang Li,Wen Zhang, JiandongChen,TingWang,Ling Jang,Wei Zhang, Xiaotao Li, Chuangui Wang. P14ARF inhibits the functions of adenovirus E1A oncoprotein. Biochemical Journal 2011,434(2):275-85.

 Guosheng Song*, Jia Shen*, Ronggui Hu, Chun Li, Qian Wang, RujiaZou, Zhigang Chen, Zongyi Qin, and Junqing Hu. Hydrophilic Molybdenum Oxide Nanomaterials with Controlled Morphology and Strong Plasmonic Absorption for Photothermal Ablation of Cancer Cells. ACS Applied Materials & Interfaces 2014, 6(6):3915-22. (* Co-first author)

 Chun Li, Junqing Hu, Wenyao Li, Guosheng Song, Jia Shen*. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment. Biomaterials Science 2016, 20;5(1):77-88. (* Corresponding author)

 J Wang, W Li, Y Ge, J Shen*, Y Zhao, Y Zhang, J Yuan. Design and synthesis of porous TiO 2@ C nanotube bundles with enhanced supercapacitive performance. Ceramics International 2017, 43 (2): 2876-80. (* Corresponding author)